Hepatitis C Treatment Market By Drug Type (Interferons, Ribavirin, Direct-Acting Antivirals (DAA) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025

A hepatitis C is inflammatory disease of the liver caused by infection with hepatitis C virus (HCV). Increasing prevalence hepatitis C, improved diagnostic techniques, easy availability of treatment medication and strong presence of pipeline molecules are driving the growth of hepatitis C treatment market globally.

The report titled “Hepatitis C treatment Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall hepatitis C treatment market along with the market size and estimates for the duration 2015 to 2025. The research study covers in-depth analysis of market segments based on drug type and different geographical regions.  Geographically, the global hepatitis C treatment market is studied for the following regional markets:   

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of LATAM
• Middle East and Africa
  • GCC
  • Rest of MEA
  •  

Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global hepatitis C treatment market. In depth analysis of pipeline molecule for key products hepatitis C treatment, global epidemiology data for hepatitis C have been included in report. 

Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global hepatitis C treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global hepatitis C treatment market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.  

Based on drug type, the global hepatitis C treatment market is segmented as follows:

• Interferons
  • Peginterferon alfa-2a
  • Peginterferon alfa-2b
  • Interferon alfa-2b
• Ribavirin
• Direct-Acting Antivirals (DAA)
  • Protease Inhibitor
    • Paritaprevir
    • Simepravir
    • Grazoprevir
  • Polymerase Inhibitors
  • Other Drugs
  •  

Hepatitis C is inflammatory disease of the liver caused by infection with hepatitis C virus (HCV). Medications and duration of HCV treatment depend on a number of factors such as genotype (genetic structure of the virus), viral load, degree of liver damage and ability to tolerate the prescribed treatment. For the purpose of the study hepatitis C treatment market is segmented on the basis of drug type such as interferons, ribavirin and direct acting antivirals. It is studied that direct acting antivirals (DAA) will show significant market growth during forecast period due to its safety and effectiveness in treatment of hepatitis C. DAA are newer approach to treat hepatitis C and it increase the chance of cure, combinations of tablets have a cure rate of more than 90%. Furthermore, due to target specificity DAA have fewer adverse effects in treatment of hepatitis C. Newly approved medications such as zepatier (elbasvir /grazoprevir), Epclusa (sofosbuvir /velpatasvir), Mavyret (glecaprevir and pibrentasvir) and Vosevi (sofosbuvir, velpatasvir and voxilaprevir) are expected to show significant market growth during forecast period.

For the purpose of this study, the global hepatitis C treatment market is categorized into:

• North America
• Europe
• Asia Pacific
• Latin America (LATAM)
• Middle East and Africa (MEA)

According to the World Health Organization (WHO), approximately 71 million people have chronic hepatitis C infection. It is studied that, in the base year 2016, North America was dominating the region in the hepatitis C treatment market in terms of revenue. Factors such as large number of target population, higher cost of treatment medication, technological advances, improved diagnostic technique and upsurge in funding by the government agencies in healthcare system are assisting the growth of hepatitis C treatment market in North America. 

According to Centers for Disease Control and Prevention (CDC), 2.7-3.9 million people in the United States are infected with chronic hepatitis C. It is observed that currently, Europe is the second largest revenue generating regional market for hepatitis C treatment due to increase in prevalence of hepatitis C and high healthcare awareness. U.K., Germany and France are major revenue contributing countries in Europe. It is anticipated that Asia Pacific market will grow significantly during the forecast period due to populous countries, developing economic condition and improving healthcare infrastructure.